<p>根據 SWS Partners 最近向證券交易委員會（SEC）提交的 13F 文件，該公司在 2023 年第三季度增持了 Natera, Inc.（NASDAQ:NTRA - 免費報告）11.8% 的股份。該公司在本季度購買了 4,980 股後，持有該醫療研究公司 47,037 股股票。Natera 佔 SWS Partners 投資組合的 1.8%，是其第 12 大持股。截至最近的 SEC 文件，SWS Partners 在 Natera 的持股價值為 7,572,000 美元。</p>
<ul>
<li>3 家不為人知的醫療保健公司</li>
</ul>
<p>其他機構投資者和對沖基金最近也買賣了該公司的股票。Blue Trust Inc.在第三季度增持了 Natera 23.1% 的股份。Blue Trust Inc.目前持有 431 股該醫療研究公司的股票，價值 69,000 美元，此前在該期間內又購買了 81 股。CWM LLC 在第三季度增持了 Natera 的股份 72.2%。CWM LLC 目前持有 70,925 股該醫療研究公司的股票，價值 11,417,000 美元，此前在上個季度又購買了 29,740 股。Swedbank AB 在第三季度增持了 Natera 的股份 7.3%。Swedbank AB 目前持有 45,170 股該醫療研究公司的股票，價值 7,271,000 美元，此前在上個季度又購買了 3,090 股。Vontobel Holding Ltd.在第三季度增持了 Natera 的股份 192.5%。Vontobel Holding Ltd.目前持有 8,531 股該醫療研究公司的股票，價值 1,373,000 美元，此前在該期間內又購買了 5,614 股。最後，Yousif Capital Management LLC 在第三季度增持了 Natera 4.5% 的股份。Yousif Capital Management LLC 目前持有 1,682 股該醫療研究公司的股票，價值 271,000 美元，此前在上個季度又購買了 72 股。機構投資者和對沖基金持有該公司 99.90% 的股份。</p>
<h2>分析師評級變動</h2>
<p>多家券商對 NTRA 發佈了報告。法國巴黎銀行將 Natera 的股票評級上調至 “持有”，並在 10 月 27 日的報告中設定了 172.00 美元的目標價。BTIG Research 在 12 月 5 日的研究報告中將 Natera 的目標價從 230.00 美元上調至 260.00 美元，並給予該公司 “買入” 評級。巴克萊在 12 月 15 日的報告中將 Natera 的目標價從 230.00 美元上調至 270.00 美元，並給予該股票 “增持” 評級。斯蒂芬斯在 11 月 13 日的報告中將 Natera 的目標價從 197.00 美元上調至 235.00 美元，並給予該公司 “增持” 評級。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Natera 股票的 “賣出（d-）” 評級。十五位分析師對該股票給予了買入評級，三位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat 的數據，Natera 目前的平均評級為 “適度買入”，共識目標價為 231.18 美元。</p>
<ul>
<li>Myriad Genetics 因遺傳癌症檢測而股價飆升</li>
</ul>
<p><strong>查看我們最新的 Natera 股票分析</strong></p>
<h2>Natera 的內部買賣</h2>
<p>在相關消息中，內部人士 Solomon Moshkevich 於 12 月 12 日星期五出售了 4,692 股該公司的股票。該股票以 230.76 美元的平均價格出售，總交易額為 1,082,725.92 美元。出售後，該內部人士在公司中持有 113,065 股，價值約為 26,090,879.40 美元。此交易代表其持股減少了 3.98%。該出售在向證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。此外，首席執行官 Steven Leonard Chapman 於 12 月 1 日星期一出售了 4,400 股 Natera 股票。該股票以 238.07 美元的平均價格出售，總交易額為 1,047,508.00 美元。出售完成後，首席執行官直接持有 140,416 股該公司的股票，價值 33,428,837.12 美元。該交易使其持股減少了 3.04%。有關此出售的更多詳細信息可在官方 SEC 披露中找到。在上個季度，內部人士出售了 365,164 股公司股票，價值 76,621,909 美元。公司內部人士持有該公司 5.63% 的股份。</p>
<h2>Natera 股票表現</h2>
<p>Natera 股票在週五開盤價為 233.74 美元。Natera, Inc.的 52 周低點為 125.38 美元，52 周高點為 246.90 美元。該公司的市值為 323.3 億美元，市盈率為-102.07，貝塔值為 1.63。該股票的 50 日移動平均線為 218.14 美元，200 日移動平均線為 181.36 美元。</p>
<p>Natera（NASDAQ:NTRA - 獲取免費報告）最近於 11 月 7 日發佈了季度財報。該醫療研究公司報告本季度每股收益（EPS）為（0.64 美元），低於分析師共識預期的（0.39 美元）25 美分。Natera 的淨利潤率為-14.61%，股本回報率為-25.07%。該公司本季度的收入為 5.9218 億美元，而分析師預期為 5.1455 億美元。在去年同期，該公司每股收益為（0.26 美元）。該公司的收入同比增長 34.7%。分析師預計 Natera, Inc.在當前財年將發佈-1.49 的每股收益。</p>
<h2>Natera 公司簡介</h2>
<p>（免費報告）</p>
<p>Natera 是一家全球診斷公司，開發和商業化無細胞 DNA 及其他基因檢測技術用於臨牀應用。該公司專注於三個主要領域：生殖健康（包括無創產前檢測和攜帶者篩查）、腫瘤學（用於最小殘留病和復發監測的腫瘤信息檢測）以及器官移植（用於檢測移植物損傷的無細胞 DNA 檢測）。Natera 結合實驗室檢測、專有生物信息學和臨牀報告，為臨牀醫生和患者提供個性化的基因信息。</p>
<p>主要產品包括 Panorama，一種無創產前檢測，篩查胎兒染色體異常和特定單基因疾病；Horizon 攜帶者篩查，用於遺傳性疾病；Signatera，一種個性化的腫瘤信息檢測，用於檢測癌症患者的最小殘留病和監測治療反應；以及 Prospera，一種供體來源的無細胞 DNA 檢測，用於評估器官排斥的風險。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比 Natera 更好的股票</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將騰飛</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Natera 嗎？</h2>
<p>在考慮 Natera 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而 Natera 並不在名單上。</p>
<p>雖然 Natera 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NTRA

<p>SWS Partners 在第三季度增持了 Natera, Inc.的股份，增幅為 11.8%，目前持有 47,037 股，市值為 757 萬美元。其他投資者也調整了他們的持倉。分析師的評級意見不一，普遍目標價為 231.18 美元。內部人士出售了股份，減少了他們的持股比例。Natera 的股票開盤價為 233.74 美元，市值為 323.3 億美元</p>

<p>SWS Partners grew its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 11.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,037 shares of the medical research company's stock after buying an additional 4,980 shares during the quarter. Natera comprises 1.8% of SWS Partners' investment portfolio, making the stock its 12th biggest holding. SWS Partners' holdings in Natera were worth $7,572,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根據 SWS Partners 最近向證券交易委員會（SEC）提交的 13F 文件，該公司在 2023 年第三季度增持了 Natera, Inc.（NASDAQ:NTRA - 免費報告）11.8% 的股份。該公司在本季度購買了 4,980 股後，持有該醫療研究公司 47,037 股股票。Natera 佔 SWS Partners 投資組合的 1.8%，是其第 12 大持股。截至最近的 SEC 文件，SWS Partners 在 Natera 的持股價值為 7,572,000 美元。</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不為人知的醫療保健公司</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in Natera by 23.1% in the third quarter. Blue Trust Inc. now owns 431 shares of the medical research company's stock valued at $69,000 after acquiring an additional 81 shares during the period. CWM LLC increased its holdings in shares of Natera by 72.2% in the 3rd quarter. CWM LLC now owns 70,925 shares of the medical research company's stock valued at $11,417,000 after purchasing an additional 29,740 shares in the last quarter. Swedbank AB increased its holdings in shares of Natera by 7.3% in the 3rd quarter. Swedbank AB now owns 45,170 shares of the medical research company's stock valued at $7,271,000 after purchasing an additional 3,090 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company's stock valued at $1,373,000 after purchasing an additional 5,614 shares during the period. Finally, Yousif Capital Management LLC boosted its holdings in Natera by 4.5% during the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company's stock worth $271,000 after buying an additional 72 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也買賣了該公司的股票。Blue Trust Inc.在第三季度增持了 Natera 23.1% 的股份。Blue Trust Inc.目前持有 431 股該醫療研究公司的股票，價值 69,000 美元，此前在該期間內又購買了 81 股。CWM LLC 在第三季度增持了 Natera 的股份 72.2%。CWM LLC 目前持有 70,925 股該醫療研究公司的股票，價值 11,417,000 美元，此前在上個季度又購買了 29,740 股。Swedbank AB 在第三季度增持了 Natera 的股份 7.3%。Swedbank AB 目前持有 45,170 股該醫療研究公司的股票，價值 7,271,000 美元，此前在上個季度又購買了 3,090 股。Vontobel Holding Ltd.在第三季度增持了 Natera 的股份 192.5%。Vontobel Holding Ltd.目前持有 8,531 股該醫療研究公司的股票，價值 1,373,000 美元，此前在該期間內又購買了 5,614 股。最後，Yousif Capital Management LLC 在第三季度增持了 Natera 4.5% 的股份。Yousif Capital Management LLC 目前持有 1,682 股該醫療研究公司的股票，價值 271,000 美元，此前在上個季度又購買了 72 股。機構投資者和對沖基金持有該公司 99.90% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of brokerages have issued reports on NTRA. BNP Paribas raised shares of Natera to a &#34;hold&#34; rating and set a $172.00 target price for the company in a report on Monday, October 27th. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, December 5th. Barclays lifted their price objective on Natera from $230.00 to $270.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, December 15th. Stephens upped their target price on Natera from $197.00 to $235.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Natera in a research note on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Natera currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $231.18.</p>
<div class="lb-trans"><p>多家券商對 NTRA 發佈了報告。法國巴黎銀行將 Natera 的股票評級上調至 “持有”，並在 10 月 27 日的報告中設定了 172.00 美元的目標價。BTIG Research 在 12 月 5 日的研究報告中將 Natera 的目標價從 230.00 美元上調至 260.00 美元，並給予該公司 “買入” 評級。巴克萊在 12 月 15 日的報告中將 Natera 的目標價從 230.00 美元上調至 270.00 美元，並給予該股票 “增持” 評級。斯蒂芬斯在 11 月 13 日的報告中將 Natera 的目標價從 197.00 美元上調至 235.00 美元，並給予該公司 “增持” 評級。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Natera 股票的 “賣出（d-）” 評級。十五位分析師對該股票給予了買入評級，三位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat 的數據，Natera 目前的平均評級為 “適度買入”，共識目標價為 231.18 美元。</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 因遺傳癌症檢測而股價飆升</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on Natera</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Natera 股票分析</strong></p>
</div><h2>Insider Buying and Selling at Natera</h2>
<div class="lb-trans"><h2>Natera 的內部買賣</h2>
</div><p>In related news, insider Solomon Moshkevich sold 4,692 shares of the firm's stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92. Following the sale, the insider owned 113,065 shares in the company, valued at approximately $26,090,879.40. This trade represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,400 shares of Natera stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00. Following the completion of the sale, the chief executive officer directly owned 140,416 shares of the company's stock, valued at $33,428,837.12. The trade was a 3.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 365,164 shares of company stock valued at $76,621,909. Corporate insiders own 5.63% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Solomon Moshkevich 於 12 月 12 日星期五出售了 4,692 股該公司的股票。該股票以 230.76 美元的平均價格出售，總交易額為 1,082,725.92 美元。出售後，該內部人士在公司中持有 113,065 股，價值約為 26,090,879.40 美元。此交易代表其持股減少了 3.98%。該出售在向證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。此外，首席執行官 Steven Leonard Chapman 於 12 月 1 日星期一出售了 4,400 股 Natera 股票。該股票以 238.07 美元的平均價格出售，總交易額為 1,047,508.00 美元。出售完成後，首席執行官直接持有 140,416 股該公司的股票，價值 33,428,837.12 美元。該交易使其持股減少了 3.04%。有關此出售的更多詳細信息可在官方 SEC 披露中找到。在上個季度，內部人士出售了 365,164 股公司股票，價值 76,621,909 美元。公司內部人士持有該公司 5.63% 的股份。</p>
</div><h2>Natera Stock Performance</h2>
<div class="lb-trans"><h2>Natera 股票表現</h2>
</div><p>Natera stock opened at $233.74 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $246.90. The company has a market capitalization of $32.33 billion, a price-to-earnings ratio of -102.07 and a beta of 1.63. The stock has a fifty day moving average of $218.14 and a two-hundred day moving average of $181.36.</p>
<div class="lb-trans"><p>Natera 股票在週五開盤價為 233.74 美元。Natera, Inc.的 52 周低點為 125.38 美元，52 周高點為 246.90 美元。該公司的市值為 323.3 億美元，市盈率為-102.07，貝塔值為 1.63。該股票的 50 日移動平均線為 218.14 美元，200 日移動平均線為 181.36 美元。</p>
</div><p>Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period in the previous year, the business earned ($0.26) EPS. The firm's revenue was up 34.7% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Natera（NASDAQ:NTRA - 獲取免費報告）最近於 11 月 7 日發佈了季度財報。該醫療研究公司報告本季度每股收益（EPS）為（0.64 美元），低於分析師共識預期的（0.39 美元）25 美分。Natera 的淨利潤率為-14.61%，股本回報率為-25.07%。該公司本季度的收入為 5.9218 億美元，而分析師預期為 5.1455 億美元。在去年同期，該公司每股收益為（0.26 美元）。該公司的收入同比增長 34.7%。分析師預計 Natera, Inc.在當前財年將發佈-1.49 的每股收益。</p>
</div><h2>Natera Company Profile</h2>
<div class="lb-trans"><h2>Natera 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.</p>
<div class="lb-trans"><p>Natera 是一家全球診斷公司，開發和商業化無細胞 DNA 及其他基因檢測技術用於臨牀應用。該公司專注於三個主要領域：生殖健康（包括無創產前檢測和攜帶者篩查）、腫瘤學（用於最小殘留病和復發監測的腫瘤信息檢測）以及器官移植（用於檢測移植物損傷的無細胞 DNA 檢測）。Natera 結合實驗室檢測、專有生物信息學和臨牀報告，為臨牀醫生和患者提供個性化的基因信息。</p>
</div><p>Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.</p>
<div class="lb-trans"><p>主要產品包括 Panorama，一種無創產前檢測，篩查胎兒染色體異常和特定單基因疾病；Horizon 攜帶者篩查，用於遺傳性疾病；Signatera，一種個性化的腫瘤信息檢測，用於檢測癌症患者的最小殘留病和監測治療反應；以及 Prospera，一種供體來源的無細胞 DNA 檢測，用於評估器官排斥的風險。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Natera</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Natera 更好的股票</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將騰飛</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=NTRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Natera Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Natera 嗎？</h2>
</div><p>Before you consider Natera, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Natera 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而 Natera 並不在名單上。</p>
</div><p>While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Natera 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

SWS Partners 購買了 Natera, Inc. $NTRA 的股票